Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
4(15%)
Results Posted
57%(4 trials)
Terminated
4(15%)

Phase Distribution

Ph phase_3
1
4%
Ph phase_4
1
4%
Ph phase_2
6
23%
Ph phase_1
18
69%

Phase Distribution

18

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution26 total trials
Phase 1Safety & dosage
18(69.2%)
Phase 2Efficacy & side effects
6(23.1%)
Phase 3Large-scale testing
1(3.8%)
Phase 4Post-market surveillance
1(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

58.3%

7 of 12 finished

Non-Completion Rate

41.7%

5 ended early

Currently Active

4

trials recruiting

Total Trials

26

all time

Status Distribution
Active(5)
Completed(7)
Terminated(5)
Other(9)

Detailed Status

unknown9
Completed7
Terminated4
Recruiting4
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
4
Success Rate
63.6%
Most Advanced
Phase 4

Trials by Phase

Phase 118 (69.2%)
Phase 26 (23.1%)
Phase 31 (3.8%)
Phase 41 (3.8%)

Trials by Status

not_yet_recruiting14%
unknown935%
withdrawn14%
terminated415%
completed727%
recruiting415%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT04615429Phase 2

Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS

Completed
NCT05705024Phase 2

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Recruiting
NCT03211793Phase 1

Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis

Recruiting
NCT04466098Phase 2

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Completed
NCT03901235Phase 1

MSC Intratissular Injection in Crohn Disease Patients

Recruiting
NCT02585622Phase 1

NEPHSTROM for Diabetic Kidney Disease

Terminated
NCT04345601Phase 1

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

Completed
NCT04445454Phase 1

Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

Recruiting
NCT06171906Phase 4

Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Not Yet Recruiting
NCT02012153Phase 1

Mesenchymal Stromal Cells in Kidney Transplant Recipients

Terminated
NCT04400032Phase 1

Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome

Completed
NCT01522716Phase 1

Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease

Terminated
NCT02057965Phase 2

Mesenchymal Stromal Cell Therapy in Renal Recipients

Unknown
NCT03509870Phase 1

Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds

Terminated
NCT02055625Phase 1

Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease

Withdrawn
NCT02387151Phase 1

Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients

Completed
NCT00957931Phase 2

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

Completed
NCT02565459Phase 1

MSC and Kidney Transplant Tolerance (Phase A)

Unknown
NCT02260375Phase 1

MSC Therapy in Liver Transplantation

Unknown
NCT02323789Phase 1

Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa

Unknown

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
26